dpp-4 inhibitors and glp-1 agonists Mechanism of action for GIP, analogues DPP4 in do not combine dpp-4 inhibitors

Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases

Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Your Patients With Obesity, Without T2D high risk for cardiovascular disease

Highlights of Prescribing Information: Victoza (liraglutide) injection, for subcutaneous use

Avoiding high-fat foods is particularly important, as dietary fat further delays gastric emptying beyond the medication's effect

A potential role for dendritic cell/macrophage-expressing dpp4 in obesity-induced visceral inflammation

Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus